Figure 4. Combined overexpression of Rab1B/MMP9 further improves predictive efficiency for outcome of CRC patients. (A) OS and PFS of patients with high or low Rab1B expression in those with low-expression of MMP9. (B) OS and PFS of patients with high or low Rab1B expression in those with high-expression of MMP9. (C) OS and PFS of patients who were stratified into three risk groups by the combined risk score of Rab1B and MMP9 proteins. Kaplan-Meier survival was used to predict the outcomes of CRC patients with low, intermediate or high combined risk score.